Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 2 of 15

  1. C24-50

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  2. CBAF312D2301

    Novartis Pharmaceuticals

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  3. CEP-1347 10mg

    Teva Pharma GmbH

    Parkinson Disease

    phase 3 small molecule terminated

    1 trial

  4. CFTY720D2311

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  5. CLOU064C12301

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  6. CLOU064C12302

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  7. CLOU064C12306

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  8. CLOU064P12301

    Novartis Pharmaceuticals

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  9. CN012-0023

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  10. CN012-0024

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  11. CN012-0025

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  12. CN012-0051

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  13. CN012-0052

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  14. CN0120020

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule active

    1 trial

  15. CN0120056

    Bristol-Myers Squibb Australia Pty Ltd

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  16. CN42097

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  17. COMB157G23101

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  18. COMB157G2399

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  19. COMB157G3301

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  20. Cladribine (MAVENCLAD®)

    United Therapeutics Europe Ltd

    Advanced Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  21. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 small molecule terminated

    1 trial

  22. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  23. Dipraglurant

    Addex Therapeutics

    Parkinson Disease

    phase 3 small molecule terminated

    2 trials

  24. EFC16035

    Genzyme Europe B.V.

    Primary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  25. EFC17919A

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  26. EFC17919B

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  27. EP0224

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  28. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 small molecule completed

    1 trial

  29. Eslicarbazepine acetate (BIA 2-093)

    Bial Portela & Companhia S.A.

    Partial Epilepsy in Children and Adolescents

    phase 3 small molecule completed

    1 trial

  30. Fingolimod

    Novartis Pharmaceuticals

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  31. Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  32. GA 20 mg/mL

    Teva Pharma GmbH

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  33. GN41791

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 other active

    1 trial

  34. GV-971

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 3 small molecule on hold

    1 trial

  35. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    4 trials

  36. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    5 trials

  37. GWP42003-P 20 mg/kg/Day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    3 trials

  38. Gantenerumab

    Hoffmann-La Roche

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial

  39. Glatiramer Acetate (DB)

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  40. Glatiramer Acetate (GA) 40 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  41. Glatiramer Acetate 20 mg/0.5 mL

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  42. Glatiramer acetate (GA)

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  43. I5T-MC-AACO

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  44. IM047-050

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  45. INTENSIFY BD

    Disc Medicine

    Bipolar depression

    phase 3 small molecule active

    1 trial

  46. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 small molecule terminated

    2 trials

  47. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 small molecule completed

    1 trial

  48. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.